Characterization of the Analgesic Effect of CBD in Healthy, Normal Volunteers
Launched by UNIVERSITY OF CALIFORNIA, LOS ANGELES · Apr 21, 2016
Trial Information
Current as of May 08, 2025
Completed
Keywords
ClinConnect Summary
This within-subject, double-blind, placebo-controlled study will assess the analgesic and subjective effects of a range of CBD doses (0, 200, 400, or 800 mg, po). Volunteers will participate in 4 outpatient laboratory sessions over the course of 4 weeks during which the analgesic effects of CBD will be assessed using the Cold-Pressor Test (CPT), a laboratory model of pain which has predictive validity for the clinical use of analgesics. The order of CBD dose will be randomized across participants. Secondary measures will include subjective and physiologic effects of CBD.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Able to perform study procedures
- • Women practicing an effective form of birth control
- Exclusion Criteria:
- • Female subjects who are currently pregnant or breastfeeding.
- • Current illicit drug use
- • Presence of significant medical illness
- • History of heart disease
- • Request for drug treatment
- • Current parole or probation
- • Recent history of significant violent behavior
- • Major psychiatric disorder
- • Current use of any prescription or over-the-counter medication
- • Current pain
- • Clinically significant Raynaud's syndrome
About University Of California, Los Angeles
The University of California, Los Angeles (UCLA) is a prestigious academic institution renowned for its commitment to research and innovation in the biomedical field. As a clinical trial sponsor, UCLA leverages its cutting-edge facilities, expert faculty, and collaborative environment to advance medical knowledge and improve patient care. The university is dedicated to conducting rigorous clinical research that adheres to the highest ethical standards, aiming to translate scientific discoveries into effective therapies and interventions. Through its diverse array of clinical trials, UCLA seeks to address critical health challenges while fostering the development of future healthcare leaders.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
Patients applied
Trial Officials
Ziva D Cooper, PhD
Principal Investigator
New York State Psychiatric Institute / CUMC
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials